evaluating the therapeutic potential of pik3ca-derived public neoantigens
Published 2 years ago • 248 plays • Length 3:25Download video MP4
Download video MP3
Similar videos
-
1:05
the prognostic and potentially therapeutic value of liquid biopsy in multiple myeloma
-
1:48
investigating the proteasome stress response as a potential novel therapeutic target in myeloma
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
2:41
cell avidity as a predictor of t-cell efficacy
-
1:45
the role of non-covalent btkis in the era of covalent btkis for b-cell malignancies
-
1:40
new therapeutic approaches targeting xpo1-overexpression in tp53-mutated myeloid malignancies
-
1:06:04
itp: novel treatments
-
1:02:27
john chaput | a nucleic acid approach to antibody therapeutics
-
1:02:23
mpo-injectivity and topologically ordered peps
-
6:07
a crispr approach to hematological research
-
2:14
a new classification for identifying high-risk myeloma based on cytogenetic abnormalities
-
2:01
immunoprecipitation assay to identify target genes in leukemia | protocol preview
-
1:50
the prognostic value of serum paraprotein response kinetics in transplant-eligible ndmm
-
0:44
unmet needs in aml: tp53 mutations and maintenance therapy
-
2:48
the promise of pyruvate kinase activators, such as mitapivat, for treating scd and thalassemia
-
2:50
insights into the ca057-003 trial: mezigdomide, tazemetostat & dexamethasone for r/r myeloma
-
1:30
treatment response assessment in melanoma and the challenge of pseudoprogression with immunotherapy
-
1:00
proof of principle to progress treatments
-
2:12
the optimal sequencing of therapies in waldenström’s macroglobulinemia
-
3:13
how to optimally sequence agents in the expanding treatment armamentarium of multiple myeloma
-
2:45
safety and efficacy of inotuzumab ozogamicin conditioning for allosct in lymphoid malignancies
-
1:05
where do bispecific antibodies fit into the large cell lymphoma treatment landscape?